On July 1, the Centers for Medicare and Medicaid Services (CMS) launched a temporary program to cover GLP-1 agonist drugs for obese Medicare beneficiaries. The program is called the Medicare GLP-1 Bridge and will allow eligible beneficiaries to access the drugs for a $50 monthly copayment.
The program is slated to run from July 2026...
As insurance companies raise flags about the cost of GLP-1 weight loss drugs in coordination with government payer programs, the Trump administration has rescinded its plan to have insurance companies fund coverage of the obesity drugs and will have Medicare pay the cost instead.
Last year, the White House announced a landmark deal...
Authors contend semaglutide (Wegovy) and tirzepatide (Zepbound) are likely to strain health system budgets if broadly prescribed.
The Institute for Clinical and Economic Review (ICER) rated three obesity treatments—including a pending oral semaglutide formulation—as “A” compared with lifestyle changes and estimated...
Glucagon-like peptide-1 (GLP-1) medications, often branded as “miracle drugs,” are reshaping payer costs and care management, according to a Milliman issue brief measuring their effect on the total cost of care. While drug spending has surged for Medicare, Medicaid, and commercial insurers, Milliman’s analysis suggests that...
